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Effects of hormonally active environmental
agents on early child development have been
of concern, as knowledge has become avail-
able about their biological activity and about
widespread exposure. For agents that are
short-lived in the body (i.e., rapidly metabo-
lized and/or eliminated), assessment of expo-
sure biomarkers in urine is usually preferred
for several reasons: The metabolites are read-
ily detectable in urine, urine is easy to collect,
and urine generally has higher concentrations
of polar metabolites than other biologic
media. Although exposures to many of these
agents have been characterized in children
[Centers for Disease Control and Prevention
(CDC) 2005], little is known about variation
of these exposure biomarkers by race, age,
body mass index (BMI), and sex. 
The Breast Cancer and the Environment
Research Centers (BCERC) are a consortium
established by the National Institute of
Environmental Health Sciences and the
National Cancer Institute to elucidate inﬂu-
ences of environmental factors on early puber-
tal development in girls, and thereby possible
future risk for breast cancer and other chronic
diseases among women. For this purpose, the
study design employs biomarkers to assess a
variety of environmental exposures. The
highest-priority urinary exposure biomarkers
identiﬁed by the BCERC consortium are phy-
toestrogens, phthalate acids, and phenols.
Agents in these groups were selected because
they possess hormonal activity that may be
agonistic or antagonistic (Fenton 2006;
Rajapakse et al. 2002; Sohoni and Sumpter
1998); they have been detected at sufﬁciently
high concentrations to constitute a potential
risk (CDC 2005); and they were known or
expected to have adequate interindividual vari-
ability to serve as exposure markers. Exposures
to these chemicals occur chiefly through the
diet and use of household or personal care
products (Table 1) (Calafat et al. 2005; CDC
2005; Duty et al. 2005). The CDC has previ-
ously reported concentrations in child partici-
pants in the National Health and Nutrition
Examination Survey (NHANES) for some
biomarkers (CDC 2005). However, no data
are available in children for certain phenols,
including bisphenol A (BPA), a chemical
with hormonal activity relevant to pubertal
development (vom Saal and Hughes 2005).
In addition, prevalence and variability of
these exposure biomarkers have not been
described among young girls, and it is not
known how these exposures may vary by race,
geographic location, or age. In this report we
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BACKGROUND: Hormonally active environmental agents have been measured among U.S. children
using exposure biomarkers in urine. However, little is known about their variation by race, age, sex,
and geography, and no data exist for newly developed biomarkers. 
OBJECTIVE: Our goal was to characterize relevant, prevalent exposures for a study of female pubertal
development.
METHODS: In a pilot study among 90 girls from New York City, New York, Cincinnati, Ohio, and
northern California, we measured 25 urinary analytes representing 22 separate agents from three
chemical families: phytoestrogens, phthalates, and phenols. Exposures occur chieﬂy from the diet
and from household or personal care products. 
RESULTS: Participants represented four racial/ethnic groups (Asian, black, Hispanic, white), with
mean age of 7.77 years. Most analytes were detectable in > 94% of samples. The highest median
concentrations for individual analytes in each family were for enterolactone (298 µg/L),
monoethylphthalate (MEP; 83.2 µg/L), and benzophenone-3 (BP3; 14.7 µg/L). Few or no data
have been reported previously for four metabolites: mono(2-ethyl-5-carboxypentyl) phthalate, tri-
closan, bisphenol A (BPA), and BP3; these were detected in 67–100% of samples with medians of
1.8–53.2 µg/L. After multivariate adjustment, two analytes, enterolactone and BPA, were higher
among girls with body mass index < 85th reference percentile than those at or above the 85th per-
centile. Three phthalate metabolites differed by race/ethnicity [MEP, mono(2-ethylhexyl) phtha-
late, and mono-3-carboxypropylphthalate]. 
CONCLUSIONS: A wide spectrum of hormonally active exposure biomarkers were detectable and
variable among young girls, with high maximal concentrations (> 1,000 µg/L) found for several
analytes. They varied by characteristics that may be relevant to development.
KEY WORDS: biomarkers, children, exposure, phenols, phthalates, phytoestrogen, urine. Environ
Health Perspect 115:116–121 (2007). doi:10.1289/ehp.9488 available via http://dx.doi.org/ [Online
19 October 2006]provide initial information on levels of
biomarkers for three chemical families of pri-
mary interest—phytoestrogens, phthalates,
and phenols—and on their distribution by
demographic factors among a subsample of
the BCERC study population. 
Methods
Participants in this pilot study were among the
ﬁrst children enrolled at three BCERC centers.
We are recruiting approximately 1,200 girls
6–8 years of age into a longitudinal study, with
the aim of following pubertal development
from its earliest stages through menarche.
Eligibility includes age 6–8 years, female sex,
and no underlying endocrine medical condi-
tions. All sites obtained informed consent from
parent or guardian and child assent, approved
by each institution’s institutional review board.
Study designs and methods were standardized
for most but not all components, because each
center retained some unique scientiﬁc aims, and
their recruitment began at different dates.
Mount Sinai School of Medicine (MSSM) is
recruiting black and Latina girls from clinics,
schools, and community centers in East
Harlem in New York City; the sample popula-
tion from the University of Cincinnati/
Cincinnati Children’s Hospital (Cincinnati) is
recruited from and examined at schools or
through a breast cancer registry; the Kaiser
Permanente Northern California (Kaiser) study
group is recruited from the Kaiser health main-
tenance organization (HMO) membership in
the San Francisco Bay area. At all sites, a base-
line questionnaire was completed by the girl’s
parent or guardian (usually the mother) that
included a detailed medical history, product use
and exposures, exercise, diet, and demographic
variables. Self-reported race/ethnicity included
white, black, American Indian, Paciﬁc Islander,
or Asian, as well as Hispanic ethnicity. There
were 10 Hispanics of Mexican origin at MSSM
who did not report a race but who were identi-
fied by interviewers as Native Americans by
ascertaining child and parental birthplace and
native language (Mexican Indians). For the
purposes of this report, race/ethnicity was classi-
ﬁed as black (including black Hispanic), non-
black Hispanic, non-Hispanic white, or
non-Hispanic Asian.
Height and weight were measured using
calibrated scales and stadiometers by inter-
viewers who had been trained and certified
uniformly across all three sites. BMI was calcu-
lated as weight/height-squared (kilograms per
square meter) and then classified as < 85th
national percentile, age- and sex-specific, or
≥ 85th percentile (Himes and Dietz 1994),
using CDC growth charts (CDC 2000). In
this CDC data set, the 85th percentile BMI
cut points for girls in the ﬁrst month of 6, 7,
and 8 years of age are 17.100, 17.626, and
18.317 kg/m2, respectively. Urine specimens
were collected at the time of the baseline exam-
ination or in a 6-month follow-up visit
(Cincinnati). MSSM and Kaiser collected spot
specimens at baseline, and Cincinnati collected
early morning voids. Each center submitted 30
urine samples to CDC for determining the
concentrations of phthalate metabolites, phe-
nols, phytoestrogens, and creatinine (to nor-
malize for urine dilution). Samples from
MSSM and Cincinnati were selected randomly
from the samples donated before December
2005 with at least 40 mL of urine. Kaiser sent
the first 30 samples collected with sufficient
volume. The study size was limited by bud-
getary constraints and by the need to conduct
the pilot study at an early stage of recruitment.
Laboratory techniques used by CDC for
measuring the selected exposure biomarkers in
urine have been published. Brieﬂy, metabolites
are deconjugated enzymatically, because these
agents are excreted almost entirely as conju-
gated metabolites. Matrix removal and analyte
enrichment are accomplished by solid phase
extraction, and instrumental analysis is done
with high performance liquid chromatography–
tandem mass spectrometry using isotope
dilution quantification (Kato et al. 2005;
Kuklenyik et al. 2004; Rybak et al. 2006; Ye
et al. 2005a). The laboratory is certified
according to the Clinical Laboratories
Improvement Act, and procedures incorporate
quality control (QC) measures to ensure accu-
racy and precision of results, including annual
proﬁciency testing compliance (Norrgran et al.
2006). A laboratory batch must meet quality
control criteria, including acceptable blanks,
or the batch is entirely reanalyzed. Results are
blank-corrected. Enterodiol data for two girls
were not available because these results did not
fulfill the quality assurance/quality control
requirements. Creatinine was measured using
an enzymatic reaction on a Roche Hitachi 912
chemistry analyzer (Roche Hitachi, Basel
Switzerland). 
We performed statistical analyses using
SAS (version 9.1.3 for PC; SAS Institute Inc.,
Cary, NC). Because of the unequal distribu-
tion of characteristics among sites, we first
used nonparametric methods to examine vari-
ation of exposure biomarker concentrations in
relation to study characteristics. For analytes
detected in > 60% of samples, we then per-
formed multivariate analyses adjusting for age,
race/ethnicity, site, BMI, and season of sample
collection using the general linear model
(GLM) procedure, which accommodates
unbalanced designs. For age, we computed
Spearman correlations with each biomarker.
Using the Kruskal-Wallis test of rank sums
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Table 1. Biomarkers, their parent compounds, and examples of their environmental sources.
Chemical class and examples Abbreviation  Main parent compound (if applicable) Exposure sources
Phytoestrogens  Dietary intake
Isoﬂavones (genistein, daidzein) Soy products, including processed meats, meat 
substitutes, breads, and protein food bars
Lignans (enterolactone) Flax, seeds, grains
Phthalate metabolites  Industrial and personal product additives
Mono(2-ethylhexyl) phthalate MEHP Di(2-ethylhexyl) phthalate  Soft plastic including tubing, especially polyvinyl chloride 
(DEHP) (PVC; e.g., sometimes present in clear food wrap)
Mono(3-carboxypropyl) phthalate MCPP Di-n-octyl phthalate Soft plastic
Monobenzyl phthalate MBzP Butylbenzyl phthalate Vinyl ﬂooring, adhesives
Monoethyl phthalate MEP  Diethyl phthalate (DEP) Shampoo, scents, soap, lotion, cosmetics
Monomethyl phthalate MMP Dimethyl phthalate (DMP) Insect repellant, plastic
Mono-n-butyl phthalate, mono-isobutyl phthalate MBP, MiBP Dibutyl phthalate (DBP),  Adhesives, caulk, cosmetics
diisobutyl phthalate (DiBP)
Phenols  Commercial and personal products and additives
Bisphenol A BPA Polycarbonate containers and coatings (cans, cups), 
dental sealant
Benzophenone-3(2-hydroxy-4-methoxy-benzophenone) BP3 Sunscreen
Triclosan [5-chloro-2-(2,4-dichlorophenoxy)phenol] TRCS Microbicide in cleaning ﬂuids
2,4-Dichlorophenol and trichlorophenols 24DCP, 245TCP, 246TCP Phenoxy- and other derivatives Herbicides
2,5-Dichlorophenol 25DCP 4-dichlorobenzene Mothballs
ortho-Phenylphenol o-PP Fungicide
4-tert-Octylphenol 4-t-OP Detergent surfactant(NPAR1WAY procedure with Wilcoxon
option), we compared medians of the creati-
nine-corrected concentrations (micrograms
per gram creatinine) by race/ethnicity, site,
BMI, and season (coded as Summer = June,
July, August vs. other seasons; use of several
products listed in Table 1 was considered
likely to vary by season). For exposure bio-
markers whose medians exhibited differences
with respect to these characteristics [see
Supplemental Materials, Table 1 (http://www.
ehponline.org/docs/2006/9488/suppl.pdf)],
we then examined whether the multivariate
geometric means were significantly different
across characteristic levels using the
LSMEANS option of the GLM procedure.
Four Asians were retained in the multivariate
analyses, with racial/ethnic differences
reported only for blacks, Hispanics, and
whites but not Asians. In parametric analyses,
we used log-transformed values of the urinary
metabolite concentrations to normalize the
distribution and we substituted the value
LOD/√2 for results below the limit of detec-
tion (LOD) following the CDC practice
(Wolff et al. 2005). 
Results
Participants represented four racial/ethnic
groups (Asian, black, Hispanic, white) and
three geographic locations (New York City,
Cincinnati metropolitan area, and the San
Francisco Bay area of California; Table 2).
Mean age was 7.77 years at date of sample col-
lection (range, 6.4–9.2). Samples collected at
Kaiser were almost all from 7-year-old girls
(29 of 30); there were two 6-year-old girls
from Cincinnati and nine from MSSM.
Race/ethnicity varied by site, with Kaiser and
Cincinnati girls mainly white (> 60%) or
black, and with no whites at MSSM. All four
Asians were from Kaiser, and most Hispanics
(18 of 22) were from MSSM. Compared with
national data (CDC 2000), 32% of girls were
≥ 85th percentile of BMI, and the distribu-
tions of BMI within sites were similar.
Samples from Kaiser were all collected in sum-
mer; no samples from Cincinnati and nine
from MSSM were collected in summer. 
Eighteen of the 25 analytes were detected
in at least 94% of the samples (Table 3).
Phytoestrogens as a group had the highest
concentrations (e.g., median 298 µg/L for
enterolactone), and all six phytoestrogens
were detected in > 98% of samples. Phthalate
metabolites were intermediate in concentra-
tion, with 9 of the 10 biomarkers detected in
> 94% of samples. Phenols had the lowest
concentrations and were least detected (only 3
of the 9 were detected in > 94% of samples).
Seventeen exposure biomarkers had medians
> 10 µg/L (10 ppb), and six had medians > 50
µg/L. Four phytoestrogens, four phthalates,
and two phenols had maximum values
> 1,000 µg/L (1 ppm). The ranges for 10 of
25 exposure biomarkers encompassed at least
3 orders of magnitude (e.g., 1–1,000 µg/L).
The highest individual biomarker measure-
ment was for benzophenone-3 (BP3; 26,700
µg/L). To verify that the very high BP3 uri-
nary measurements reflected absorbed dose
rather than surface contamination during
sample collection, storage, or analysis, we
measured free (i.e., unbound) BP3 in the nine
samples having concentrations >1,000 µg/L.
The concentrations of unbound BP3 were
minimal, < 1–20 µg/L (data not shown), con-
sistent with excretion of absorbed BP3 as con-
jugated species (Ye et al. 2005b).
Multivariate adjusted concentrations of
creatinine-corrected exposure biomarkers
(geometric means) are presented in Table 4
according to race/ethnicity, geographic site,
BMI, and season of collection; included are the
20 analytes that were detected in at least 60%
of samples. Differences in the medians (unad-
justed) by characteristics are shown in the
Supplemental Material, Table 1 (http://www.
ehponline.org/docs/2006/9488/suppl.pdf).
Compared with the unadjusted values, there
were fewer signiﬁcant associations in the multi-
variate models for race (5 vs. 8), site (3 vs. 9),
and season (1 vs. 6). Enterolactone and BPA
differed significantly with regard to BMI
(< 85th percentile vs. ≥ 85th percentile). The
adjusted geometric means of three phthalate
metabolites varied by race/ethnicity, with
whites having lower concentrations of mono(2-
ethylhexyl) phthalate (MEHP) and monoethyl
phthalate (MEP) but higher mono(3-carboxy-
propyl) phthalate (MCPP). Among the phe-
nols, 2,5-dichlorophenol (25DCP) was higher
in blacks than whites, and BP3 was higher in
whites. O-Desmethylangolensin (O-DMA),
25DCP, and 2,4-dichlorophenol (24DCP) dif-
fered across the three study sites. BP3 was
higher in samples collected in summer.
Patterns by race and season for MEHP, MEP,
MCPP, 25DCP, and 24DCP remained the
same if the geometric means were adjusted for
age, race, BMI, and season but not for site.
When the correlation between age as a contin-
uous variable and each analyte was examined,
it was signiﬁcantly associated only with equol
(micrograms equol/grams creatinine; rS –0.26,
p = 0.013). In the multivariate model for equol
[ln, micrograms per gram creatinine], the beta
for age (years) was –0.44 (p = 0.029, adjusted
for race/ethnicity, geographic site, BMI, and
season of collection).
The strongest correlations between individ-
ual biomarkers within a family were seen
among those arising from the same parent
compound (e.g., rS = 0.79–0.99 among four
di(2-ethylhexyl) phthalate [DEHP] metabo-
lites: mono(2-ethyl-5-carboxypentyl) phthalate
[MECPP], mono(2-ethyl-5-hydroxyhexyl)
phthalate [MEHHP], (2-ethyl-5-oxohexyl)
phthalate [MEOHP], and MEHP; data not
shown). We computed correlations between
creatinine and the urinary exposure biomarkers
to examine the appropriateness of creatinine-
corrections for dilution. The lowest correla-
tions were seen for BP3 (rS = –0.03, p = 0.758)
and O-DMA (rS = 0.24, p = 0.022); correla-
tions of creatinine with other biomarkers were
fairly strong (rS > 0.3, p < 0.01; data not
shown). Associations of phthalate metabolites
with creatinine were stronger (rS = 0.50–0.72)
than for phytoestrogens (rS = 0.33–0.52, not
including  O-DMA) and phenols (rS =
0.42–0.54 for triclosan, 25DCP, BPA, and
24DCP). Because BP3 was not related to uri-
nary creatinine, it may be inappropriate to cor-
rect for dilution using creatinine (Hauser et al.
2004; Miller et al. 2004). When we examined
Wolff et al.
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Table 2. Characteristics of the study population, BCERC pilot study, 2004–2005.
No. per site
Characteristic No. (%) MSSM Cincinnati Kaiser
Age at sample collection (years)a
6.0–6.9 11 (12.2) 9 2 0
7.0–7.9 57 (63.3) 9 19 29
≥ 8.0 22 (24.4) 12 9 1
Race/ethnicity
Asian 4 (4.4) 0 0 4
Black 26 (28.9) 12 9 5
Hispanic 22 (24.4) 18 1 3
White 38 (42.2) 0 20 18
Site
Cincinnati 30 (33.3)
MSSM 30 (33.3)
Kaiser 30 (33.3)
BMI for ageb
< 85th percentile 61 (67.8) 21 19 21
≥ 85th percentile 29 (32.2) 9 11 9
Collection timec
June–August 39 (43.3) 9 0 30
Other months 51 (56.7) 21 30 0
aSome samples were collected at a visit 6 months after the baseline visit. bAvailable: http://www.cdc.gov/growthcharts/
(CDC 2000). cOctober 2004 to September 2005.BP3 in relation to the characteristics in Table
4 using the concentration as micrograms per
liter (uncorrected for creatinine), we obtained
almost identical results. The range of creati-
nine was 7.6–255 mg/dL with 9 samples < 20
mg/dL, which could potentially inﬂuence the
data in Tables 3 and 4 by overinflating the
creatinine-corrected values. We examined the
distribution of values for the nine low-creati-
nine samples in those exposure biomarkers
that varied signiﬁcantly by the factors in Table
4; they were fairly evenly distributed in terms
of concentrations, and excluding them from
the multivariate adjusted models did not alter
the differences seen in the exposure biomark-
ers with regard to characteristics described
above. In addition, in models where biomark-
ers were not creatinine-corrected (micrograms
per liter), we observed results similar to those
in Table 4, except that two associations were
not signiﬁcant (BPA with BMI, p = 0.11; and
24DCP by site, p = 0.13). 
Discussion
This pilot study of peripubertal girls exam-
ined urinary biomarkers of exposures among
three chemical families that possess known or
likely hormonal activity. Biomarkers from
these families appear to be ubiquitous, have
wide variability, and show relatively high uri-
nary concentrations in 6- to 9-year-old girls,
suggesting that they are suitable for study of
exposure–outcome associations related to
puberty. Among the 25 exposure biomarkers
measured in this study, we had initially iden-
tified eight compounds as high priority for
the epidemiologic study, based on criteria of
having prevalent, high exposure levels, toxico-
logic relevance, and exposure biomarker relia-
bility. These included three phytoestrogens
(enterolactone, daidzein, genistein), three
phthalate metabolites (mono-n-butyl phtha-
late [MBP], monobenzyl phthalate [MBzP],
MEP), and two phenols (BPA, nonylphenol).
Seven of these biomarkers were detected in at
least 94% of samples, and the ranges of con-
centrations were wide, from the LOD (< 1)
to > 26,000 µg/L (minimum–maximum).
Nonylphenol was not determined because
CDC as yet has no optimal biomarker for this
compound (Calafat et al. 2005).
Levels of phytoestrogen and phthalate
metabolites in this study were similar to those
reported in the NHANES 2001–2002 chil-
dren (CDC 2005), although enterodiol
appeared to be higher and MBzP and
monomethyl phthalate (MMP) lower in our
study population. MECPP and MEP had the
highest levels of the 10 phthalate metabolites
measured. MECPP, a DEHP metabolite, has
not been previously reported in NHANES nor
in school-age children. The relationship of
equol with age could be of interest, but it was
the only analyte related to age. This association
could also be attributable to population char-
acteristics that can be explored in the future,
such as diet. Two biomarkers (enterolactone
and BPA) varied by BMI, and three phtha-
lates differed by race. Relationships of phtha-
lates with race/ethnicity were quite similar to
those reported for all ages in the NHANES
2001–2002—for example, MEP and MEHP
were highest in blacks and MCPP highest in
whites (CDC 2005) (the CDC report does
not provide race-specific data for children).
One biomarker varied by season (BP3) and
three by site (O-DMA, 25DCP, 24DCP),
differences that may reﬂect diverse exposures;
alternatively, these observations may be attrib-
uted to the unequal distribution of character-
istics by site, a notion supported by the
finding that both BP3 and 25DCP also dif-
fered by race. Differences by race and BMI
may also be attributed to other confounding
factors, including socioeconomic status (SES),
that were not available for consideration. SES
may affect body size, dietary habits, and prod-
uct use, for example.
Among the four DEHP metabolites meas-
ured, MEHP differed signiﬁcantly by race after
multivariate adjustment, whereas the trends for
the three oxidative metabolites of DEHP were
similar but not statistically signiﬁcant (Table
4). It is possible that we did not detect signiﬁ-
cant racial/ethnic trends for the three DEHP
oxidative metabolites because of limited sample
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Table 3. Distribution of BCERC phytoestrogen, phthalate, and phenol and biomarkers for all sites combined, 2004–2005.
Range (µg/L) Geometric mean  Geometric mean NHANES 50th
Analyte No. No. > LOD  LOD (µg/L) Percent > LOD Low High Median (µg/L) [GSD (µg/L)] [GSD (µg/gC)] percentilea (µg/L)
Phytoestrogens
Enterolactone  90 90 0.3 100.0 4.6 6730.0 298.0 269.0 (4.1) 420.0 (3.7) 329.0
Daidzein 90 90 0.3 100.0 2.4 9690.0 98.0 112.0 (5.7) 175.0 (5.2) 72.7
Enterodiol 88 88 0.3 100.0 1.0 548.0 63.7 54.8 (3.3) 86.5 (2.8) 35.4
Genistein 90 90 0.3 100.0 1.2 5360.0 50.1 60.4 (5.4) 94.3 (4.7) 31.5
Equol 90 89 0.3 98.9 0.2 485.0 10.5 10.9 (4.1) 17.0 (3.5) 13.6
O-DMA 90 89 0.2 98.9 0.1 3210.0 5.7 5.7 (9.3) 8.9 (8.6) 5.7
Phthalates
MECPPb 90 90 0.25 100.0 5.9 2260.0 53.2 50.3 (3.1) 78.5 (2.5)
MEHHPb 90 90 0.32 100.0 1.4 1699.0 25.9 28.0 (3.4) 43.8 (2.7) 32.9
MEOHPb 90 90 0.45 100.0 1.3 1070.0 17.8 18.8 (3.3) 29.3 (2.6) 22.6
MEHPb 90 85 0.90 94.4 0.6 110.0 3.2 3.3 (3.0) 5.2 (2.7) 4.4
MEP 90 90 0.40 100.0 5.3 2580.0 83.2 75.7 (3.9) 118.0 (3.1) 71.9
MBP 90 88 0.40 97.8 0.3 363.0 37.4 28.2 (3.4) 44.1 (2.4) 32.4
MBZP 90 89 0.11 98.9 0.1 191.0 22.2 18.4 (4.0) 28.7 (2.8) 37.0
MIBP 90 87 0.26 96.7 0.2 144.0 7.7 7.1 (3.6) 11.1 (2.5) 4.4
MCPP 90 90 0.16 100.0 0.4 76.9 6.3 6.1 (2.9) 9.5 (2.1) 6.6
MMP 90 18 1.00 20.0 < LOD 15.6 < LOD < LOD < LOD 1.8
Phenols
BP3 90 86 0.34 95.6 < 0.2 26700.0 14.7 19.7 (14.6) 30.8 (15.5) 82.3
Triclosan 90 61 2.27 67.8 < 1.6 956.0 7.2 10.9 (6.5) 17.1 (5.5) 12.5
25DCP 90 88 0.12 97.8 < 0.1 3120.0 7.1 9.0 (11.9) 14.0 (9.9) 3.1
BPA 90 85 0.36 94.4 < 0.3 54.3 1.8 2.0 (3.2) 3.0 (3.0) 2.4
24DCP 90 70 0.17 77.8 < 0.1 92.7 0.9 0.9 (5.3) 1.4 (4.3) 0.6
246TCP 90 22 0.50 24.4 < LOD 6.1 < LOD < LOD < LOD 0.3
245TCP 90 21 0.10 23.3 < LOD 1.2 < LOD < LOD < LOD 0.1
4-t-OP 90 5 0.17 5.6 < LOD 0.4 < LOD < LOD < LOD 0.5
o-PP 90 3 0.10 3.3 < LOD 2.5 < LOD < LOD < LOD 0.4
Creatinine (mg/dL) 90 7.6 254.8 76.2
Abbreviations: GSD, geometric standard deviation; µg/gC, the urinary concentration (µg/L) corrected for creatinine (g/L). 
aNHANES 50th percentile values for phthalates and phytoestrogens for 6- to 11-year-old children obtained from the Third National Report on Human Exposure to Environmental
Chemicals (CDC 2005);50th-percentile values for phenols obtained from Ye et al. (2005a). bDerived from DEHP.size. It is also possible for MEHP to arise from
sample contamination or hydrolysis, whereas
the oxidative metabolites must be endogenous;
however, this is unlikely to explain racial/
ethnic variability. Alternatively, although over-
all exposures to DEHP may have been fairly
uniform, recent ambient exposures to DEHP
may have varied by race/ethnicity in this pop-
ulation. In another study, racial/ethnic differ-
ences in MEP levels were attributed to greater
use of cologne by blacks and Hispanics (Duty
et al. 2005). If recent exposures were responsi-
ble for the racial/ethnic differences in our data,
a possibility would be that MEHP as the ﬁrst
metabolite formed might differ by race/ethnic-
ity, reflecting mainly the most recent expo-
sures. Another possible explanation is that
there may be racial/ethnic variability in the
primary but not the secondary DEHP meta-
bolic routes. MEHP is the initial metabolite of
DEHP, and it can undergo further oxidation
through separate pathways, producing
MECPP by one route and MEHHP and
MEOHP by another. Racial/ethnic differences
in the secondary pathways could be smaller
than for MEHP formation. In addition, the
oxidative metabolites have longer half-lives
[10–15 hr vs. 5 hr for MEHP (Koch et al.
2006)], possibly constituting a more inte-
grated measure of long-term exposures that
vary less by race/ethnicity.
The high correlations observed among
four DEHP metabolites signify a common
source of exposure from the parent compound
(Silva et al. 2006). The proportion of MECPP
(> 50% of the total of four metabolites
reported here) is consistent with previous
research suggesting that infants have a much
higher proportion of MECPP (66%) than
adults (32%) (Silva et al. 2006). Among other
phthalate metabolites, MCPP and MEP,
which differed signiﬁcantly by race but in dif-
ferent directions, were not highly correlated
with each other (rS = 0.33), supporting differ-
ent product origins and environmental expo-
sures for these agents. 
The relationships of the urinary exposure
biomarkers to creatinine levels are of interest.
One site collected early-morning (but not
ﬁrst-morning) voids, which may reﬂect differ-
ent accumulated exposures than daytime spot
samples that creatinine correction cannot
resolve entirely. However, collection time is
not likely to bias our exposure measures,
because the adjusted means differed by site for
only three analytes in two chemical families,
and speciﬁc exposures are as likely to explain
these findings as collection time. As recog-
nized by others, care must be taken in normal-
izing urinary analytes for dilution because the
excretory mechanisms are not the same for
creatinine and certain chemicals (Hauser et al.
2004; Miller et al. 2004). This possibility is
evident in our study where the correlations
between creatinine and endocrine disruptor
biomarkers varied, from zero (BP3) to 0.72
(mono-isobutyl phthalate [MiBP]), suggesting
that excretion or metabolic capacity may affect
these associations, possibly related to the
amount of bound (e.g., glucuronidated) versus
unbound metabolites. However, in agreement
with previous research (Ye et al. 2005b), our
data show that even at very high concentra-
tions, BP3 is excreted mostly conjugated in
urine; in contrast, MEP is mostly unconju-
gated (Silva et al. 2003). Unlike creatinine,
glucuronide conjugates are actively excreted by
tubular secretion, which may explain in part
the low correlation of BP3 with creatinine as
well as the wide range of correlations between
creatinine and these biomarkers (see Hauser
et al. 2004 and references therein). An alterna-
tive to correcting for urinary concentration is
urinary specific gravity (Hauser et al. 2004;
Miller et al. 2004), but this measurement was
not performed on our samples. 
The differences in exposure biomarkers by
race/ethnicity and BMI are potentially relevant
to pubertal development which is known to be
associated with these characteristics (Herman-
Giddens et al. 1997). Furthermore, the associa-
tions of enterolactone and BPA with BMI and
of phthalate metabolites with race are notable
because these biomarkers did not vary by other
factors in our data. Although the differences we
observed are suggestive only, because the sam-
ple size is small and unbalanced with regard to
some characteristics, we used a conservative
approach, considering only a limited number
of a priori comparisons. Furthermore, the ﬁnd-
ings for phthalate metabolites were consistent
with earlier reports. In general, concentrations
of the 25 urinary exposure biomarkers we
measured are far higher than those of more
widely studied environmental agents such as
Wolff et al.
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Table 4. Geometric means (µg/g creatinine) of phytoestrogen, phthalate, and phenol biomarkers (those ≥ 60% LOD) adjusted for age, race, site, BMI, and season,
2004–2005.
BMI for age
< 85th ≥ 85th Season of 
Race/ethnicity Site reference reference sample  collection
Asian Black Hispanic White Cincinnati MSSM Kaiser percentile percentile Summer Other season
Total (n = 90) (n = 4) (n = 26) (n = 22) (n = 38) (n = 30) (n = 30) (n = 30) (n = 61) (n = 29) (n = 39) (n = 51)
Phytoestrogens
Enterolactone 174.0 414.0 388.0 287.0 292.0 185.0 495.0 513.0 174.0* 236.0 378.0
Daidzein 53.4 166.0 188.0 205.0 154.0 69.8 234.0 115.0 161.0 97.1 190.0
Enterodiol 157.0 58.5 81.5 97.1 113.0 65.4 107.0 107.0 79.9 99.9 85.4
Genistein 52.2 83.7 96.8 111.0 81.8 56.3 123.0 68.4 100.0 55.5 123.0
Equol 12.1 10.7 20.2 17.9 17.9 20.1 8.9 16.7 12.9 10.7 20.2
O-DMA 0.9 12.0 6.6 7.5 7.1 1.6 10.1* 6.7 3.5 3.5 6.8
Phthalates
MECPPa 119.0 80.7 98.1 69.2 91.5 111.0 71.5 86.6 93.4 100.0 80.9
MEHHPa 58.2 55.0 43.3 42.0 48.3 64.8 37.8 43.0 56.1 53.0 45.5
MEOHPa 37.3 33.8 29.0 29.0 31.6 41.5 25.2 28.8 35.8 33.6 30.6
MEHPa 8.3 7.9 4.5 4.3* 5.9 7.2 5.0 5.5 6.5 6.4 5.6
MEP 66.1 194.0 231.0 73.5* 161.0 100.0 111.0 102.0 144.0 140.0 105.0
MBP 48.2 39.0 50.9 44.4 46.7 49.7 40.3 43.3 47.6 42.1 48.9
MBZP 8.0 24.2 33.2 35.7 24.9 22.3 18.9 20.4 23.5 21.1 22.7
MiBP 15.3 10.1 11.3 11.8 10.4 14.6 11.3 10.8 13.3 10.2 14.1
MCPP 5.5 6.5 9.6 12.0* 9.3 7.8 7.2 8.8 7.3 8.5 7.6
Phenols
BP3 42.2 21.7 14.9 92.7* 14.5 25.6 101.0 26.9 41.8 83.8 13.4*
Triclosan 6.7 22.0 16.3 14.3 21.2 14.8 8.0 15.8 11.7 13.3 13.9
25DCP 16.2 28.5 15.6 8.8* 6.7 85.0 7.1* 12.3 20.6 10.9 23.0
BPA 2.7 3.1 3.4 2.3 3.2 2.6 2.8 3.7 2.2* 2.9 2.8
24DCP 1.5 1.7 1.3 1.2 0.9 3.4 0.9* 1.3 1.6 1.1 1.8
aAll derived from DEHP. *p-Value < 0.05 forone or more LSMEANS tests between characteristic levels (for race, signiﬁcance is not indicated if it was found only for Asians). Urinary environmental biomarkers in girls
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1,1´-dichloro-2,2´-bis(4-chlorophenyl)ethylene
(DDE) and elemental lead (CDC 2005). In
addition, some of these agents have relatively
potent hormonal activity. In yeast assays, for
example, BPA and butylbenzyl phthalate (the
parent compound of MBzP) have greater
antiandrogenic and estrogenic activity than
DDE (Sohoni and Sumpter 1998). However,
the proportional biological effects of these
exposures in humans are not known. Several
exposure biomarkers reported here have not
previously been measured in children nor in
different parts of the United States. On the
basis of this pilot study, we are considering the
potential relevance to child development of
additional exposures that were not originally
planned for study, and we are exploring alter-
natives to creatinine correction. If we identify
any of these biomarkers as either protective or
detrimental in terms of child maturation, the
levels of these chemicals in the body may be
modiﬁable because they are derived from the
diet or ambient environment or from personal
product use. Additional studies are under way
to identify sources of these agents in our popu-
lation and to assess the temporal variation of
urinary metabolites among children.
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